GO
Loading...

Glaxo's Avandia Prescriptions Drop After Study

Doctors in the United States have shunned GlaxoSmithKline's diabetes drug Avandia since a study was published last week linking the drug to heart-attack risk, according to daily prescription data.

Information from market research group Impact RX indicates Avandia's share of the market for newly prescribed oral anti-diabetics fell to approximately zero from around 10% in the two days after the article was published on May 21.

"This reaction is far worse than we had anticipated and suggests that there could be as much as 22% downside risk to GSK's near term earnings, suggesting that there is still further downside to GSK's share price, " Deutsche Bank analysts, citing the prescription data, said in a note.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • CNBC's Kayla Tausche reports on the results of the Fed's bank stress test. All 31 banks have cleared capital requirement levels and had sufficient capital before shareholder payout. Perspective, with Jack Mohr, thestreet.com, and Jeff harte, Sandler O'Neill.

  • Dallas Mavericks owner Mark Cuban said in a recent blog this tech bubble is worse than the one in 2000. Cuban discusses the lack of liquidity in this current tech market; the IPO market, angel investors and crowd funding.

  • Dallas Mavericks owner Mark Cuban has outlined concerns for angel investors. Steve Brotman, Alpha Venture Partners founder, provides his take on the warning and says Cuban is over-exaggerating.